{"product_id":"prescribing-by-numbers-drugs-and-the-definition-of-disease-paperback","title":"Prescribing by Numbers: Drugs and the Definition of Disease - Paperback","description":"\u003cdiv\u003e\u003cp style=\"text-align: right;\"\u003e\u003ca href=\"https:\/\/reportcopyrightinfringement.com\/\" target=\"_blank\" rel=\"nofollow\"\u003e\u003cb\u003eReport copyright infringement\u003c\/b\u003e\u003c\/a\u003e\u003c\/p\u003e\u003c\/div\u003e\u003cp\u003eby \u003cb\u003eJeremy A. Greene\u003c\/b\u003e (Author)\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eWinner, 2009 Rachel Carson Prize, Society for the Social Studies of ScienceWinner, 2012 Edward Kremers Award, American Institute of the History of Pharmacy\u003c\/p\u003e\u003cp\u003eThe second half of the twentieth century witnessed the emergence of a new model of chronic disease--diagnosed on the basis of numerical deviations rather than symptoms and treated on a preventive basis before any overt signs of illness develop--that arose in concert with a set of safe, effective, and highly marketable prescription drugs. In \u003ci\u003ePrescribing by Numbers\u003c\/i\u003e, physician-historian Jeremy A. Greene examines the mechanisms by which drugs and chronic disease categories define one another within medical research, clinical practice, and pharmaceutical marketing, and he explores how this interaction has profoundly altered the experience, politics, ethics, and economy of health in late-twentieth-century America. \u003c\/p\u003e\u003cp\u003e\u003ci\u003ePrescribing by Numbers\u003c\/i\u003e highlights the complex historical role of pharmaceuticals in the transformation of disease categories. Greene narrates the expanding definition of the three principal cardiovascular risk factors--hypertension, diabetes, and high cholesterol--each intersecting with the career of a particular pharmaceutical agent. Drawing on documents from corporate archives and contemporary pharmaceutical marketing literature in concert with the clinical literature and the records of researchers, clinicians, and public health advocates, Greene produces a fascinating account of the expansion of the pharmaceutical treatment of chronic disease over the past fifty years. \u003c\/p\u003e\u003cp\u003eWhile acknowledging the influence of pharmaceutical marketing on physicians, Greene avoids demonizing drug companies. Rather, his provocative and comprehensive analysis sheds light on the increasing presence of the subjectively healthy but highly medicated individual in the American medical landscape, suggesting how historical analysis can help to address the problems inherent in the program of pharmaceutical prevention.\u003c\/p\u003e\u003ch3\u003eFront Jacket\u003c\/h3\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eThe second half of the twentieth century witnessed the emergence of a new model of chronic disease--diagnosed on the basis of numerical deviations rather than symptoms and treated on a preventive basis before any overt signs of illness develop--that arose in concert with a set of safe, effective, and highly marketable prescription drugs. Physician-historian Jeremy A. Greene examines the mechanisms by which drugs and chronic disease categories define one another within medical research, clinical practice, and pharmaceutical marketing, and he explores how this interaction has profoundly altered the experience, politics, ethics, and economy of health in late-twentieth-century America. His provocative analysis sheds light on the increasing presence of the subjectively healthy but highly medicated individual in the American medical landscape, suggesting how historical perspective can help to address the problems inherent in the program of pharmaceutical prevention.\u003c\/p\u003e\u003cp\u003eGreene describes the relationship between advances in treatment, the incentives of manufacturers, and the effect on the public of increased attention to prevention . . . The risk-benefit trade-offs of the quantitative approach are complex, and Greene's historical revelations are timely.--\u003ci\u003eNew England Journal of Medicine\u003c\/i\u003e\u003c\/p\u003e\u003cp\u003eOne of the best, and most significant, books published recently on the development of medical practice and the pharmaceutical industry in the U.S. in the second half of the twentieth century.--\u003ci\u003eSocial History of Medicine\u003c\/i\u003e\u003c\/p\u003e\u003cp\u003eGreene focuses on the question of how public health priorities became closely aligned with the pharmaceutical industry's marketing practices . . . [and] offers a nuanced description of the development of 'therapeutics of risk reduction' with multiple lines of influence, subtle power shifts, and gains and losses for patients and physicians.--\u003ci\u003eChemical Heritage\u003c\/i\u003e\u003c\/p\u003e\u003cp\u003eA gripping story . . . Greene warns us in his superb book that things are not always as they are claimed.--\u003ci\u003eYale Journal for Humanities in Medicine\u003c\/i\u003e\u003c\/p\u003e\u003cp\u003e \u003cb\u003eJeremy A. Greene\u003c\/b\u003e is a fellow in the Department of Social Medicine at Harvard Medical School and a resident in the Department of Medicine at Brigham and Women's Hospital.\u003c\/p\u003e--Robert Aronowitz, M.D., History and Sociology of Science Department, University of Pennsylvania \"Nursing History Review\"\u003ch3\u003eBack Jacket\u003c\/h3\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eThe second half of the twentieth century witnessed the emergence of a new model of chronic disease--diagnosed on the basis of numerical deviations rather than symptoms and treated on a preventive basis before any overt signs of illness develop--that arose in concert with a set of safe, effective, and highly marketable prescription drugs. Physician-historian Jeremy A. Greene examines the mechanisms by which drugs and chronic disease categories define one another within medical research, clinical practice, and pharmaceutical marketing, and he explores how this interaction has profoundly altered the experience, politics, ethics, and economy of health in late-twentieth-century America. His provocative analysis sheds light on the increasing presence of the subjectively healthy but highly medicated individual in the American medical landscape, suggesting how historical perspective can help to address the problems inherent in the program of pharmaceutical prevention.\u003c\/p\u003e\u003cp\u003e\"Greene describes the relationship between advances in treatment, the incentives of manufacturers, and the effect on the public of increased attention to prevention . . . The risk-benefit trade-offs of the quantitative approach are complex, and Greene's historical revelations are timely.\"--\u003ci\u003eNew England Journal of Medicine\u003c\/i\u003e\u003c\/p\u003e\u003cp\u003e\"One of the best, and most significant, books published recently on the development of medical practice and the pharmaceutical industry in the U.S. in the second half of the twentieth century.\"--\u003ci\u003eSocial History of Medicine\u003c\/i\u003e\u003c\/p\u003e\u003cp\u003e\"Greene focuses on the question of how public health priorities became closely aligned with the pharmaceutical industry's marketing practices . . . [and] offers a nuanced description of the development of 'therapeutics of risk reduction' with multiple lines of influence, subtle power shifts, and gains and losses for patients and physicians.\"--\u003ci\u003eChemical Heritage\u003c\/i\u003e\u003c\/p\u003e\u003cp\u003e\"A gripping story . . . Greene warns us in his superb book that things are not always as they are claimed.\"--\u003ci\u003eYale Journal for Humanities in Medicine\u003c\/i\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eJeremy A. Greene\u003c\/b\u003e is a fellow in the Department of Social Medicine at Harvard Medical School and a resident in the Department of Medicine at Brigham and Women's Hospital.\u003c\/p\u003e\u003ch3\u003eAuthor Biography\u003c\/h3\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eJeremy A. Greene\u003c\/b\u003e is an associate professor of medicine and the Elizabeth Treide and A. McGehee Harvey Chair in the history of medicine at Johns Hopkins University School of Medicine. He is the author of \u003ci\u003eGeneric: The Unbranding of Modern Medicine\u003c\/i\u003e and coeditor of \u003ci\u003ePrescribed: Writing, Filling, Using, and Abusing the Prescription in Modern America, \u003c\/i\u003e both published by Johns Hopkins.\u003c\/p\u003e\n            \u003cdiv\u003e\n\u003cstrong\u003eNumber of Pages:\u003c\/strong\u003e 336\u003c\/div\u003e\n            \u003cdiv\u003e\n\u003cstrong\u003eDimensions:\u003c\/strong\u003e 0.76 x 9 x 6 IN\u003c\/div\u003e\n            \u003cdiv\u003e\n\u003cstrong\u003ePublication Date:\u003c\/strong\u003e November 01, 2008\u003c\/div\u003e\n            ","brand":"BooksCloud","offers":[{"title":"Default Title","offer_id":52239302787346,"sku":"9780801891007","price":54.63,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0941\/2211\/5346\/files\/WjNzT1o4Y1Ztb1BNbUFVMTRUV2xGQT09.webp?v=1777875799","url":"https:\/\/ckbookstore.net\/products\/prescribing-by-numbers-drugs-and-the-definition-of-disease-paperback","provider":"CK BOOKSTORE","version":"1.0","type":"link"}